Last week, Vertex Pharmaceuticals ($VRTX) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's...
Shares of NeurogesX, already badly beaten up over the past year, tanked after regulators raised questions about the efficacy...
After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public...
Shares of Orexigen Therapeutics ($OREX) shot up 18% yesterday after the biotech laid out a special protocol assessment pact...
Merck says that vorapaxar, its troubled blood thinner once considered the jewel in Schering-Plough's crown when the pharma...
Following a three-year review of its new approach to R&D, GlaxoSmithKline ($GSK) today revealed that it has decided to...
The FDA isn't convinced that Amgen ($AMGN) needs another bone-metastasis indication for its new drug Xgeva. The drug is already...
In one of the most anticipated R&D events of the year, GlaxoSmithKline ($GSK) execs are readying a summary judgment on...
Merck today says it has the late-stage data it needs to gain an approval for a new insomnia drug, one of 5 treatments the...
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in...
